Inactivation of YAP/TAZ by approved agents and their application as anti-breast cancer stem cell drugs

2015 Fiscal Year Final Research Report

• Project/Area Number: 26830113
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Tumor therapeutics
• Research Institution: Iwate Medical University
• Principal Investigator: Oku Yusuke 岩手医科大学, 薬学部, 助教 (50626843)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: Hippo経路 / YAP/TAZ / スタチン / ダサチニブ / パゾパニブ

Outline of Final Research Achievements

We identified fluvastatin, dasatinib, pazopanib as agents inhibiting the function of oncogenic transcriptional co-activator, YAP/TAZ. They activate Hippo pathway and inhibit their nuclear localization. The sensitivity to these drugs of breast and colon cancer cell lines were correlated with the dependence on YAP/TAZ. Combination of these drugs efficiently reduced viability of MDA-MB-231 breast cancer cell lines. Furthermore, combination of these drugs with classical anti-cancer drugs synergistically reduced the viability of MDA-MB-231. These results suggest that these agents are effective for breast cancer cells with YAP/TAZ activation.

Free Research Field

シグナル伝達